Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AtriCure, Inc.ATRC · Entity 2704 | Chief Mktg & Strategy Officer | July 29, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AtriCure, Inc.
Report date July 29, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,219 |
Reported balance
After 2026-07-29 transaction · row 1
1 source rowRow 1 · 2026-07-29 · Sale · Disposed 6,182 · Balance 100,219 F1: This transaction was executed in multiple trades at prices ranging from $38.62 to $39.28 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $38.62 to $39.28 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2019 Filed May 2, 2019 11:02 UTC | AtriCure, Inc. ATRC · Entity 2704 | Exercise / conversionCommon Stock | 15,000 | $18.30 | $274,500.00 |
DisclosureSEC source: 0001209191-19-026889 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were exercised pursuant to a 10b5-1 trading plan. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 20:53 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 12,569 | $27.64 | $347,407.16 |
DisclosureSEC source: 0001209191-19-024778 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,068 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.40 to $27.98 per share. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 11:16 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 18,845 | $30.77 | $579,860.65 |
DisclosureSEC source: 0001209191-19-017223 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,637 F2 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award. Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 11:16 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 10,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017223 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,482 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 11:54 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 4,000 | $30.32 | $121,280.00 |
DisclosureSEC source: 0001209191-18-047250 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,920 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.07 to $30.84 per share. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 20:17 UTC | AtriCure, Inc. ATRC · Entity 2704 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034664 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,920 F1 · price: No consideration was received in connection with this gift to charity. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:28 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 4,000 | $23.05 | $92,200.00 |
DisclosureSEC source: 0001209191-18-030916 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,920 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.93 to $23.39 per share. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:16 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 14,803 | $17.71 | $262,161.13 |
DisclosureSEC source: 0001209191-18-016413 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,920 F2 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to Restricted Stock Awards. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:16 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 25,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016413 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,723 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 21:11 UTC | AtriCure, Inc. ATRC · Entity 2704 | SaleCommon Stock | 4,000 | $17.03 | $68,120.00 |
DisclosureSEC source: 0001209191-18-010820 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,997 F1 · shares: These shares were sold pursuant to a 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.62 to $17.40 per share. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 06, 2018 Filed Jan 9, 2018 13:37 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 3,182 | $17.99 | $57,244.18 |
DisclosureSEC source: 0001209191-18-002832 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,997 F1 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 21:12 UTC | AtriCure, Inc. ATRC · Entity 2704 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047434 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,179 F1 · price: No consideration was received in connection with this gift to charity. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:21 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 8,386 | $18.95 | $158,914.70 |
DisclosureSEC source: 0001209191-17-017514 · doc4.xml · nonDerivative · entry 2 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,179 F2 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to Restricted Stock Awards. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:21 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-017514 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,565 F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest 25% annually over four years from date of grant. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 21:45 UTC | AtriCure, Inc. ATRC · Entity 2704 | Tax withholdingCommon Stock | 2,432 | $18.93 | $46,037.76 |
DisclosureSEC source: 0001209191-17-003208 · doc4.xml · nonDerivative · entry 1 Noznesky Justin J · CIK 0001666600 · SVP, Mktg & Business Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,565 F1 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.